MXPA03003388A - Moleculas de proteina c o similares a las de proteina c activadas. - Google Patents

Moleculas de proteina c o similares a las de proteina c activadas.

Info

Publication number
MXPA03003388A
MXPA03003388A MXPA03003388A MXPA03003388A MXPA03003388A MX PA03003388 A MXPA03003388 A MX PA03003388A MX PA03003388 A MXPA03003388 A MX PA03003388A MX PA03003388 A MXPA03003388 A MX PA03003388A MX PA03003388 A MXPA03003388 A MX PA03003388A
Authority
MX
Mexico
Prior art keywords
polypeptide
conjugate
variant
protein
apc
Prior art date
Application number
MXPA03003388A
Other languages
English (en)
Spanish (es)
Inventor
Per Ola Freskgaard
Original Assignee
Maxygen Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Aps filed Critical Maxygen Aps
Publication of MXPA03003388A publication Critical patent/MXPA03003388A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MXPA03003388A 2000-10-18 2001-10-15 Moleculas de proteina c o similares a las de proteina c activadas. MXPA03003388A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24226800P 2000-10-18 2000-10-18
DKPA200001560 2000-10-18
US30015401P 2001-06-21 2001-06-21
DKPA200100970 2001-06-21
PCT/DK2001/000679 WO2002032461A2 (en) 2000-10-18 2001-10-15 Protein c or activated protein c-like molecules

Publications (1)

Publication Number Publication Date
MXPA03003388A true MXPA03003388A (es) 2005-03-07

Family

ID=27439828

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003388A MXPA03003388A (es) 2000-10-18 2001-10-15 Moleculas de proteina c o similares a las de proteina c activadas.

Country Status (8)

Country Link
US (1) US20030027299A1 (https=)
EP (1) EP1328622A2 (https=)
JP (1) JP4071105B2 (https=)
KR (1) KR20030060915A (https=)
AU (2) AU2002210388B2 (https=)
CA (1) CA2425221A1 (https=)
MX (1) MXPA03003388A (https=)
WO (1) WO2002032461A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003232176A1 (en) * 2002-06-14 2003-12-31 Maxygen Aps Protein c variants with altered properties
AU2003280316A1 (en) * 2002-11-11 2004-06-03 Maxygen Aps Zymogen-like protein c polypeptides
WO2004113385A1 (en) * 2003-06-20 2004-12-29 Maxygen Holdings Ltd. Protein c propeptide variants
WO2005007820A2 (en) * 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
JP4707327B2 (ja) * 2004-01-27 2011-06-22 旭化成ファーマ株式会社 ポリペプタイド類の吸着防止剤
WO2006044294A2 (en) * 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
ES2349024T3 (es) * 2006-04-11 2010-12-21 Csl Behring Gmbh Metodo para aumentar la recuperacion in vivo de polipeptidos terapeuticos.
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
EP2103310A1 (en) * 2008-03-19 2009-09-23 Universiteit Maastricht Method for the prevention or treatment of ischemia reperfusion injury.
CN102105582A (zh) 2008-04-21 2011-06-22 诺沃-诺迪斯克有限公司 高糖基化人凝血因子ix
WO2010062756A2 (en) * 2008-11-03 2010-06-03 University Of Rochester Preventing and treating sepsis
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
PL3131572T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
PT3137102T (pt) * 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
KR101889743B1 (ko) * 2017-03-17 2018-08-20 주식회사 유비프로틴 단백질 반감기를 증가시키는 방법
KR101955884B1 (ko) * 2017-03-17 2019-03-08 주식회사 유비프로틴 단백질 반감기를 증가시키는 방법
KR101893403B1 (ko) * 2017-03-17 2018-08-30 주식회사 유비프로틴 단백질 반감기를 증가시키는 방법
KR101947339B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Pdgfb 반감기를 증가시키는 방법
KR101955886B1 (ko) * 2017-05-05 2019-03-12 주식회사 유비프로틴 안지오포이에틴-1 반감기를 증가시키는 방법
KR101955885B1 (ko) * 2017-05-05 2019-03-08 주식회사 유비프로틴 Pdgfa 반감기를 증가시키는 방법
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270040A (en) * 1985-02-08 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5196322A (en) * 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
JP2774154B2 (ja) * 1989-08-10 1998-07-09 帝人株式会社 活性化ヒトプロテインc誘導体
ATE163048T1 (de) * 1989-12-29 1998-02-15 Zymogenetics Inc Hybrides protein c
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
JPH0892294A (ja) * 1994-09-29 1996-04-09 Teijin Ltd ヒト活性化プロテインc誘導体
EP0946715B1 (en) * 1996-11-08 2006-03-29 Oklahoma Medical Research Foundation Use of a modified protein c
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
WO2000066754A1 (en) * 1999-04-30 2000-11-09 Eli Lilly And Company Protein c derivatives
CA2400187A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives

Also Published As

Publication number Publication date
AU2002210388B2 (en) 2006-11-23
AU1038802A (en) 2002-04-29
JP2004534503A (ja) 2004-11-18
EP1328622A2 (en) 2003-07-23
JP4071105B2 (ja) 2008-04-02
WO2002032461A3 (en) 2002-09-26
KR20030060915A (ko) 2003-07-16
WO2002032461A2 (en) 2002-04-25
US20030027299A1 (en) 2003-02-06
CA2425221A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
MXPA03003388A (es) Moleculas de proteina c o similares a las de proteina c activadas.
AU2002210388A1 (en) Protein C or activated protein C like molecules
JP4472526B2 (ja) 凝血活性が増加した第VII因子または第VIIa因子変種
US8383388B2 (en) Modified coagulation factor IX polypeptides and use thereof for treatment
JP2005523723A (ja) 第VII因子または第VIIa因子のポリペプチド変種
CA2400187A1 (en) Protein c derivatives
US7226999B2 (en) Protein C or activated protein C-like molecules
EP0443874B1 (en) Vectors and compounds for expression of glycosylation mutants of human protein C
EP1090130A1 (en) Protein c derivatives
US6998122B1 (en) Protein C derivatives
CN100392079C (zh) 蛋白c或活化的蛋白c-样分子
ZA200302224B (en) Protein C or activated protein C-like molecules.
WO2003106666A2 (en) Protein c variants with altered properties
WO2004044190A2 (en) Zymogen-like protein c polypeptides
WO2004113385A1 (en) Protein c propeptide variants
AU2007320353A1 (en) Thrombin mutant
JP2005278550A (ja) 2本鎖組織プラスミノーゲンアクチベーターの製造法
HK1167679A (en) Modified coagulation factor ix polypeptides and use thereof for treatment
HK1167680A (en) Modified coagulation factor ix polypeptides and use thereof for treatment
HK1167678A (en) Modified coagulation factor ix polypeptides and use thereof for treatment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal